Helix Biopharma (OTCMKTS:HBPCF – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.07, Zacks reports.
Helix Biopharma Price Performance
Shares of HBPCF stock remained flat at $0.77 during midday trading on Friday. The firm’s 50-day simple moving average is $1.24 and its 200 day simple moving average is $1.60. The firm has a market cap of $58.81 million, a PE ratio of -19.25 and a beta of 0.11. Helix Biopharma has a 52 week low of $0.77 and a 52 week high of $1.73.
About Helix Biopharma
Helix BioPharma Corp. is a Canadian clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company’s research is centered on treatments designed to act within the tumor microenvironment, with the goal of improving the effectiveness of oncology medicines.
Its lead product candidate is L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. L-DOS47 combines a targeting antibody fragment with urease, an enzyme intended to generate ammonia in the tumor environment and potentially disrupt conditions that support tumor growth.
Read More
- Five stocks we like better than Helix Biopharma
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Helix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
